

1 Article

2 Prebiotic Dietary Fiber and Gut Health: Comparing the In Vitro  
3 Fermentations of Beta-Glucan, Inulin and Xylooligosaccharide.

4 Justin L. Carlson<sup>1†</sup>, Jennifer M. Erickson<sup>1†</sup>, Julie M. Hess<sup>1</sup>, Trevor J. Gould<sup>2</sup>, Joanne L. Slavin<sup>†</sup>

5

6 <sup>1</sup> Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Ave St. Paul, MN 55108

7 <sup>2</sup> Informatics Institute, University of Minnesota, 101 Pleasant St, Minneapolis, MN 55455

8

9 + Authors contributed equally to this work

10 \* Correspondence: [jslavin@umn.edu](mailto:jslavin@umn.edu) ; Tel.: +1 612-624-7234

11 **Abstract:** Prebiotic dietary fiber supplements are commonly consumed to help meet fiber  
12 recommendations and improve gastrointestinal health by stimulating beneficial bacteria and the  
13 production of short-chain fatty acids (SCFAs), molecules beneficial to host health. The objective of  
14 this research project was to compare potential prebiotic effects and fermentability of five  
15 commonly consumed fibers using an in vitro fermentation system measuring changes in fecal  
16 microbiota, total gas production and formation of common SCFAs. Fecal donations were collected  
17 from three healthy volunteers. Materials analyzed included: pure beta-glucan, Oatwell  
18 (commercially available oat-bran containing 22% oat  $\beta$ -glucan), xylooligosaccharides (XOS),  
19 WholeFiber (dried chicory root containing inulin, pectin, and hemi/celluloses), and pure inulin.  
20 Oatwell had the highest production of propionate at 12 h (4.76  $\mu$ mol/mL) compared to inulin,  
21 WholeFiber and XOS samples ( $p < 0.03$ ). Oatwell's effect was similar to those of the pure beta-glucan  
22 samples, both samples promoted the highest mean propionate production at 24 h. XOS resulted in  
23 a significant increase in the genus *Bifidobacterium* after 24 h of fermentation (0 h: 0.67 OTUs; 24 h:  
24 5.22 OTUs;  $p = 0.038$ ). Inulin and WholeFiber increased the beneficial genus *Collinsella*, consistent  
25 with findings in clinical studies. All analyzed compounds were fermentable and promoted the  
26 formation of beneficial SCFAs.

27 **Keywords:** prebiotic, microbiota, fermentation, dietary fiber, microbiome

28

29 1. Introduction

30 Prebiotic definitions vary among different scientific and political arenas across the world [1].  
31 Depending on the local definition, nearly all prebiotics can be classified as dietary fiber, but not all  
32 fibers are considered prebiotics [2]. The most recent definition describes a prebiotic as “a selectively  
33 fermented ingredient that results in specific changes in the composition and/or activity of the  
34 gastrointestinal microbiota, thus conferring benefit(s) upon host health” [3]. Functional  
35 characteristics of prebiotics include the ability to: resist the low pH of the stomach, resist hydrolysis  
36 by mammalian enzymes, resist absorption in the upper gastrointestinal tract, the ability to be  
37 fermented by intestinal microbiota and selectively stimulate the growth and/or activity of intestinal  
38 bacteria associated with host health and overall well-being [4,5]. Inulin, beta-glucans, and  
39 xylooligosaccharides all provide health benefits to consumers that are related to the fermentation of  
40 these compounds in the distal gastrointestinal tract, and are also considered functional fibers with  
41 many other benefits [6]. As the definition of “prebiotic” broadens to include the overall impact from  
42 the metabolism from these compounds, the category of prebiotics will expand [7]. The importance of  
43 displaying direct health benefits due to bacterial fermentation is still the driving mechanism for all  
44 prebiotics.

As our awareness and understanding of the importance of the gut microbiome and gut microbiota increases, it is imperative for consumers to understand the key differences between different forms of prebiotics, and where they can be found in various foods and food products. XOS is an emerging prebiotic with well-displayed, consistent health benefits[8] and is composed of sugar oligomers composed of xylose units [9], found naturally in fruits, vegetables, milk, honey and bamboo shoots. XOS is commonly produced from xylan containing lignocellulosic materials through various chemical methods, direct enzymatic hydrolysis, or a combination of both treatments [10–14]. Inulin is a heterogeneous blend of fructose polymers (DP<10)[15] which occurs naturally in thousands of plant species, including wheat, onion, bananas, garlic and chicory [16]. Beta-glucan is a polysaccharide composed of D-glucose monomers with beta-glycosidic linkages, present in either linear chains in grains, such as oat and barley (up to 7%), or in branched structures in fungi, yeast and certain bacteria [17]. These prebiotics, or prebiotic mixtures, each provide a unique carbon source for selective stimulation of different bacterial taxa and are important microbiota-shaping compounds.

Because no analytical method currently exists to measure the prebiotic capacity of foods in terms of their influence on gastrointestinal taxa, this field relies heavily on fecalbiotics (living or once living fecal microbial populations) to quantify the effects of these compounds. In vitro fermentation models allow for quantitative analysis of specific materials and are semi-representative models of colonic fermentation [18]. Although not a complete substitute for human studies, when paired with in vivo models, in vitro analysis can be an accurate systematic approach to analyze different parameters and end points in colonic fermentation [19].

With the recent release of the International Scientific Association for Probiotics and Prebiotics consensus statement, prebiotics have now been defined to include XOS, not previously included [20]. This paper compares the fermentation effects of XOS to previously established prebiotics (inulin and beta-glucans) in a controlled in-vitro model. To authors’ knowledge this is the first controlled in vitro study comparing the effects of XOS to these known prebiotics. The objective of this project was to compare currently available prebiotics by their ability to change specific taxa as well as compare differences in the production of gas and common short chain fatty acids (SCFA) between these products. Inulin, XOS and beta-glucan based products were chosen for this experiment because they are established and emerging prebiotics that are commonly consumed, and offer well-demonstrated health benefits to their consumers.

**2. Materials and Methods**

*2.1 Prebiotic Dietary Fibers Analyzed*

Five common prebiotic dietary fibers were chosen for this study (Table 1), including different types of beta-glucans, inulin and xylooligosaccharide supplements.

**Table 1.** Comparison Prebiotic Dietary Fibers Analyzed With In Vitro Fermentation System.

Prebiotic Dietary Fibers	Supplier Information
OatWell (Oatbran containing 28% beta-glucan)	DSM Nutritional Products, Ltd.
WholeFiber (A dried chicory root blend containing: inulin, pectin, hemi/cellulose)	WholeFiber, Inc.
Xylooligosaccharide (XOS)	AIDP, Inc.
Pure Inulin	Cargill, Inc.
Pure Beta-glucan	Megazyme, Inc.

2.2 Fecal Collection & Donor Information

Fecal samples were collected from three healthy volunteers (2 males, 1 female) under anaerobic conditions from individuals (ages 22-28) consuming non-specific Western diets, free of any antibiotic treatments in the last year, non-smokers, not affected by any known GI diseases and not consuming any supplements (Table 2). Fecal samples were anaerobically collected within 5 minutes of the start of the fermentation (Medline Specimen Collection Kit, Medline, Inc.), and homogenized immediately upon collection. All data and samples collected were done in accordance with University of Minnesota policies and procedures.

**Table 2.** Demographic Characteristics of Three Fecal Donors.

	Donor 1	Donor 2	Donor 3
Age	26	25	22
Sex	Female	Male	Male
BMI	28.1	26.3	23.0

2.3 Fermentation

Fiber samples (0.5 g) were hydrated in 40 mL of prepared sterile tricare peptone fermentation media in 100 mL serum bottles, capped, and incubated for 12 hours at 4°C. Following incubation, serum bottles were transferred to a circulating water bath at 37°C and allowed to incubate for 2 hours. Post-collection, fecal samples were mixed using a 6:1 ratio of phosphate buffer solution to fecal sample. After mixing, obtained fecal slurry was combined with prepared reducing solution (2.52 g cysteine hydrochloride, 16 mL 1N NaOH, 2.56 g sodium sulfide nonanhydride, 380 mL DD H<sub>2</sub>O) at a 2:15 ratio. 10 mL of the prepared fecal inoculum was added to each of the serum bottles, 0.8 mL Oxyrase® was added, flushed with CO<sub>2</sub>, sealed, and then immediately placed in a 37°C circulating water bath. Samples were prepared in triplicate and analyzed at 0, 12 and 24 h. Upon removal at each time point, total gas volume was measured. Then samples were divided into aliquots for analysis and 1 mL of copper sulfate (200 g/L) was added to cease fermentation. All samples were immediately frozen and stored at -80°C for further analysis.

2.4 SCFA Analysis

SCFA samples were extracted according to Schneider et al[21] with minor modifications, and analyzed with previously described methods [22].

2.5 DNA Extractions

Fecal bacteria DNA from the in vitro system were extracted using a PowerSoil DNA Isolation Kit (MO BIO Laboratories, Inc.) following the provided operating instruction, including bead beating for 20 min.

2.5.1 Primary/Secondary Amplification

The V1-V3 region of the 16S rRNA was amplified using a two-step PCR protocol. The primary amplification was done using an ABI7900 qPCR machine. The following recipe was used: 3 µl template DNA, 0.48 µl nuclease-free water, 1.2 µl 5x KAPA HiFi buffer (Kapa Biosystems, Woburn, MA), 0.18 µl 10 mM dNTPs (Kapa Biosystems, Woburn, MA), 0.3 µl DMSO (Fisher Scientific, Waltham, MA), 0.12 µl ROX (25 µM) (Life Technologies, Carlsbad, CA), 0.003 µl 1000x SYBR Green, 0.12 µl KAPA HiFi Polymerase (Kapa Biosystems, Woburn, MA), 0.3 µl forward primer (10 µM), 0.3 µl reverse primer (10 µM). Cycling conditions were: 95°C for 5 minutes, followed by 20 cycles of

98°C for 20 seconds, 55°C for 15 seconds, and 72°C for 1 minute. The primers for the primary amplification contained both 16S-specific primers (V1\_27F and V3\_V34R), as well as adapter tails for adding indices and Illumina flow cell adapters in a secondary amplification. The following primers were used (16S-specific sequences in bold): Meta\_V1\_27F (TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGAGTTTGATCMTGGCTCAG) and Meta\_V3\_534R (GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATTACCGCGGCTGCTGG).

The amplicons from the primary PCR were diluted 1:100 in sterile, nuclease-free water, and a second PCR reaction was set up to add the Illumina flow cell adapters and indices. The secondary amplification was done on a fixed block BioRad Tetrad PCR machine using the following recipe: 5 µl template DNA, 1 µl nuclease-free water, 2 µl 5x KAPA HiFi buffer (Kapa Biosystems, Woburn, MA), 0.3 µl 10 mM dNTPs (Kapa Biosystems, Woburn, MA), 0.5 µl DMSO (Fisher Scientific, Waltham, MA) 0.2 µl KAPA HiFi Polymerase (Kapa Biosystems, Woburn, MA), 0.5 µl forward primer (10 µM), 0.5 µl reverse primer (10 µM). Cycling conditions were: 95°C for 5 minutes, followed by 10 cycles of 98°C for 20 seconds, 55°C for 15 seconds, 72°C for 1 minute, followed by a final extension at 72°C for 10 minutes. The following indexing primers were used (X indicates the positions of the 8 bp indices): Forward indexing primer: AATGATACGGCGACCACCGAGATCTACACXXXXXXXXTCGTCGGCAGCGTC and Reverse indexing primer: CAAGCAGAAGACGGCATACGAGATXXXXXXXXGTCTCGTGGGCTCGG

2.5.2 Normalization and Sequencing

The samples were normalized using a SequalPrep capture-resin bead plate (Life Technologies, Carlsbad, CA) and pooled using equal volume. The final pools were quantified via PicoGreen dsDNA assay (Life Technologies, Carlsbad, CA) and diluted to 2nM. 10 µl of the 2 nM pool was denatured with 10 µl of 0.2 N NaOH, diluted to 8 pM in Illumina’s HT1 buffer, spiked with 15% phiX, heat denatured at 96°C for 2 minutes, and sequenced using a MiSeq 600 cycle v3 kit (Illumina, San Diego, CA).

2.5.3 Sequence Processing and Analysis

Generated sequence data was processed and analyzed using QIIME [23]. Fastq sequence data was processed with the University of Minnesota’s gopher-pipeline for metagenomics [24]. Sequence data had adapters removed and sliding quality trimming window by Trimmomatic [25]; primers removed and overlapping reads merged by Pandaseq [26]. Within QIIME, chimera checking done by chimera slayer, Open reference OTU picking completed with Usearch61, taxonomic identification using GreenGenes (Version 13.8) reference database, rarefied to 14,393 sequences per sample. Analysis was performed using R (R Development Core Team, 2012).

2.6 Statistical Analysis

All statistical analysis was performed using R software (R Development Core Team, 2012). Differences in means were determined using the Kruskal-Wallis ANOVA test, testing the null hypothesis that the location parameter of the groups of abundancies for a given OTU is the same. Multiple comparisons were corrected using the FDR procedure. For gas and SCFA data, ANOVA with Tukey HSD was used to compare means. Significance was set for *p*-values < 0.05 for all statistical tests.


2.7 Consent

Voluntary informed consent was obtained from all fecal donors prior to this study according to University of Minnesota policies and procedures.

3. Results

3.1 Gas Production

At 12 h, the OatWell and the pure beta-glucan samples produced similar amounts of total gas (Figure 1). The XOS samples produced significantly more gas than the pure beta glucan samples ( $p < 0.01$ ) or the OatWell samples ( $p < 0.01$ ). The WholeFiber and pure inulin samples produced similar amounts of total gas ( $p = 0.102$ ), and the total gas production for both of these prebiotic dietary fibers was significantly higher than the XOS samples, ( $p < 0.01$  and  $p = 0.045$ ), respectively. At 24 h, the OatWell samples had the lowest gas production (46.2 mL) and were similar to the pure beta-glucan samples (63.7 mL;  $p = 0.498$ ). The 24 h XOS samples (74.0 mL) were also similar to the beta-glucan samples ( $p = 0.926$ ). However, the 24 h WholeFiber (109.6 mL) and pure inulin (107.1 mL) samples produced significantly more gas than XOS, beta-glucan and Oatwell samples ( $p < 0.01$ ).




**Figure 1.** Total gas production comparing fermentation differences among five prebiotic dietary fibers for three individuals at 12 h and 24 h post-exposure to fecal microbiota in an in vitro fermentation system. Data displayed are means (3 donors  $\times$  3 replicates = 9) for each prebiotic dietary fiber  $\pm$  SD. Columns with different letters are significantly different from one another within each time measurement (lowercase: 12 h; uppercase: 24 h). Data were analyzed using ANOVA with Tukey HSD ( $p < 0.05$ ).

3.2 SCFA Production

For all SCFA analysis, analysis at 12 and 24 h shows production only, from baseline corrected samples. Acetate, propionate and butyrate production is shown as  $\mu\text{mol/mL}$  of fermentation media.


Acetate production at 12 h was similar for the Oatwell, WholeFiber and beta-glucan samples (Figure 2). The XOS samples produced significantly more acetate at 12 h than the Oatwell, WholeFiber or beta-glucan samples ( $p < 0.05$ ). The inulin samples had similar amounts of acetate compared to the WholeFiber and XOS samples, and significantly more than the Oatwell ( $p = 0.024$ ) and beta-glucan ( $p = 0.013$ ) samples at 12 h. After 24 h, the inulin samples contained less acetate than the XOS samples ( $p = 0.038$ ), while the Oatwell, WholeFiber and beta-glucan samples were similar to both the XOS and inulin samples.



191

192 **Figure 2.** Acetate production at 12 h and 24 h of fermentation for five prebiotic dietary fibers  
193 displayed as  $\mu\text{mol/mL}$  of fermentation inoculum. Data displayed are means (3 donors  $\times$  3 replicates  
194 = 9) for each prebiotic dietary fiber  $\pm$  SD. Columns with different letters are significantly different  
195 from one another (lowercase: 12 h; uppercase: 24 h). Data were analyzed using ANOVA with  
196 Tukey HSD ( $p < 0.05$ ).

197 Propionate production at 12 h of fermentation was highest for the OatWell samples (4.76  
198  $\mu\text{mol/mL}$ ) and was significantly greater than the WholeFiber ( $p=0.029$ ), XOS ( $p=0.005$ ) and inulin  
199 samples ( $p=0.004$ ), and similar to the beta-glucan samples (Figure 3). At 24 h of fermentation, the  
200 Oatwell samples had the highest mean production 5.05  $\mu\text{mol/mL}$ , which was significantly greater  
201 than the XOS samples (2.58  $\mu\text{mol/mL}$ ;  $p=0.021$ ), and similar to WholeFiber, inulin and beta-glucan  
202 samples.




203

204 **Figure 3.** Propionate production at 12 h of fermentation for five prebiotic dietary fibers displayed as  
205  $\mu\text{mol/mL}$  of fermentation inoculum. Data displayed are means (3 donors  $\times$  3 replicates = 9) for each  
206 prebiotic dietary fiber  $\pm$  SD. Columns with different letters are significantly different from one  
207 another (lowercase: 12 h; uppercase: 24 h). Data were analyzed using ANOVA with Tukey HSD ( $p$   
208  $< 0.05$ ).

209 Butyrate production after 12 h of fermentation ranged from 7.30  $\mu\text{mol/mL}$  for the beta-glucan  
210 samples to 16.76  $\mu\text{mol/mL}$  for the inulin samples (Figure 4). The inulin samples had the highest  
211 average production, and were similar to the XOS (16.38  $\mu\text{mol/mL}$ ) and WholeFiber samples (12.89  
212  $\mu\text{mol/mL}$ ). The XOS samples were significantly higher than the Oatwell ( $p=0.035$ ) and beta-glucan  
213 samples ( $p=0.014$ ). At 24 h of fermentation, all five prebiotic dietary fibers were statistically similar to  
214 one another, ranging from 7.93 – 14.08  $\mu\text{mol/mL}$  due to a wide ranges in response differences  
215 between the three fecal donors used in this study.





216

217 **Figure 4.** Butyrate production at 12 h of fermentation for five prebiotic dietary fibers displayed as  
218 μmol/mL of fermentation inoculum. Data displayed are means (3 donors x 3 replicates = 9) for each  
219 prebiotic dietary fiber ± SD. Columns with different letters are significantly different from one  
220 another (lowercase: 24 h; uppercase: 24 h). Data were analyzed using ANOVA with Tukey HSD ( $p$   
221  $< 0.05$ ).

222 **3.3 Microbiota Analysis**

223 Extracted DNA from in vitro samples were sequenced using the MiSeq Illumina platforms,  
224 generating a total of 31,591,899 sequence reads. Sequencing parameters identified reads belonging to  
225 11 bacterial phyla, 61 families and 97 genera.

226 For all three donors, the phyla Bacteroidetes and Firmicutes represented >80% of all sequence  
227 reads (Figure S1) across 24 h of fermentation. At the family level, 13 families represented 85% of all  
228 sequence reads (Figure S2), while 11 genera represented >75% of all sequence reads (Figure S3). Six  
229 metrics measuring  $\alpha$ -diversity for all donors showed various degrees of grouping by donors (Figure  
230 S4), and by treatment group (Figure S5). Both Unifrac and Bray-Curtis  $\beta$ -diversity metrics  
231 (measuring pairwise dissimilarity between samples), showed similarity among technical replicates  
232 of treatment groups for each donor (Figure S6) as well as for all treatment groups for each respective  
233 donor (Figure S7).

234 After 24 h of fermentation, the Oatwell samples significantly decreased the population of  
235 SMB53 (0 h: 9.11 OTUs; 24 h: 2.11 OTUs;  $p = 0.008$ ), *Lachnospira* and *Faecalibacterium* (0 h: 26.56 OTUs;  
236 24 h: 4.44 OTUs;  $p = 0.008$  and 0 h 136.44 OTUs; 24 h: 66 OTUs;  $p = 0.022$ , respectively) (Table 3). In  
237 vivo studies with inulin, scFOS and resistant starch supplementation have all found decreases in the  
238 SMB53 genus [27,28]. No genera analyzed showed significant increases in 24 h for the Oatwell  
239 samples measured for the three fecal donors in this study. The WholeFiber samples (Table 4)  
240 significantly increased the genus *Collinsella* at 24 h compared to 0 h (0 h: 68 OTUs; 24 h: 299.78 OTUs;  
241  $p = 0.011$ ). *Bifidobacterium* populations were only significantly increased at 24 h compared to 0 h for  
242 the XOS samples (0 h: 0.67 OTUs; 24 h: 5.22 OTUs;  $p = 0.038$ ), while the same samples showed a  
243 significant decrease in *Lachnospira* and *Faecalibacterium* ( $p = 0.038$  and  $p = 0.03$ ) (Table 5). The inulin  
244 samples (Table 6) increased *Collinsella* (0 h: 55.11 OTUs; 24 h: 291.44 OTUs;  $p = 0.016$ ). The pure beta  
245 glucan samples significantly decreased *Lachnospira* and *Faecalibacterium* ( $p = 0.008$ ) (Figure 7).

246

**Table 3.** Combined changes across 24 h of fermentation for Oatwell samples of identified phyla and genera.<sup>1</sup>

Phyla & Genera	0 h	24 h	Test-Statistic	P-value
Actinobacteria				
<i>Bifidobacterium</i>	1.22	0.89	0.63	0.660
<i>Adlercreutzia</i>	1.44	3.00	1.37	0.470
<i>Collinsella</i>	48.44	140.56	6.33	0.089
Bacteroidetes				
<i>Alistipes</i>	2.56	1.33	0.55	0.674
<i>Parabacteroides</i>	135.00	155.89	0.05	0.952
<i>Bacteroides</i>	755.67	865.00	3.95	0.192
Firmicutes				
<i>Eubacterium</i>	0.44	0.56	0.20	0.817
<i>Veillonella</i>	1.11	1.22	0.01	0.980
<i>Dorea</i>	2.33	3.56	1.08	0.516
<i>Acidaminococcus</i>	3.22	10.44	0.22	0.817
<i>Clostridium</i>	7.67	8.33	0.33	0.769
<i>Anaerostipes</i>	8.11	6.00	0.52	0.674
<i>Turcibacter</i>	8.67	1.22	2.54	0.286
<i>SMB53</i>	9.11	2.11	12.83	0.008*
<i>Ruminococcus</i>	11.22	23.22	3.13	0.263
<i>Lactococcus</i>	11.67	10.67	0.00	0.980
<i>Streptococcus</i>	15.22	8.11	1.15	0.511
<i>Roseburia</i>	20.22	22.33	0.01	0.980
<i>Oscillospira</i>	21.78	36.67	4.90	0.121
<i>Lachnospira</i>	26.56	4.44	12.94	0.008*
<i>Phascolarctobacterium</i>	27.78	173.33	3.03	0.263
<i>Dialister</i>	39.56	43.00	0.88	0.560
<i>Blautia</i>	41.89	53.11	1.32	0.470
<i>Coproccoccus</i>	49.89	39.00	1.76	0.396
<i>Ruminococcus</i>	61.33	40.67	2.39	0.289
<i>Faecalibacterium</i>	136.44	66.00	9.58	0.022*
Proteobacteria				
<i>Escherichia</i>	0.44	1.44	2.13	0.325
<i>Haemophilus</i>	10.22	0.67	2.49	0.286
<i>Sutterella</i>	10.78	14.44	0.00	0.980
<i>Bilophila</i>	13.67	14.78	0.28	0.788
Verrucomicrobia				
<i>Akkermansia</i>	5.00	12.00	0.01	0.980

<sup>1</sup>Replicate samples were pooled among donor at each respective time point (3 donors x 3 replicated = 9). Samples were analyzed between differentially represented OTUs for significant changes after 24



h of fermentation compared to 0 h samples. Data were analyzed using the Kruskal-Wallis ANOVA test, with the FDR multiple comparisons correction. \*Indicates significance at  $P \leq 0.05$ .

**Table 4.** Combined changes across 24 h of fermentation for WholeFiber samples of identified phyla and genera.<sup>1</sup>

Phyla & Genera	0 h	24 h	Test-Statistic	P-value
Actinobacteria				
<i>Adlercreutzia</i>	0.89	3.89	3.61	0.239
<i>Bifidobacterium</i>	1.11	1.11	0.56	0.785
<i>Collinsella</i>	68.00	299.78	12.17	0.011*
Bacteroidetes				
<i>Alistipes</i>	1.11	0.56	0.31	0.894
<i>Parabacteroides</i>	131.44	142.00	0.07	0.913
<i>Bacteroides</i>	743.56	776.56	0.56	0.785
Firmicutes				
<i>Eubacterium</i>	1.11	0.78	0.50	0.799
<i>Veillonella</i>	1.22	1.00	0.01	0.960
<i>Dorea</i>	2.00	5.00	0.66	0.785
<i>Acidaminococcus</i>	2.67	11.33	0.22	0.894
<i>SMB53</i>	5.67	4.00	3.58	0.239
<i>Clostridium</i>	7.33	13.22	0.10	0.896
<i>Anaerostipes</i>	10.22	1.22	3.60	0.239
<i>Ruminococcus</i>	10.89	19.67	0.03	0.943
<i>Streptococcus</i>	12.67	8.78	0.57	0.785
<i>Turicibacter</i>	14.22	2.44	0.01	0.960
<i>Lachnospira</i>	14.78	72.00	4.13	0.237
<i>Oscillospira</i>	17.22	14.89	1.13	0.647
<i>Lactococcus</i>	20.44	9.22	0.12	0.896
<i>Phascolarctobacterium</i>	24.67	60.44	1.82	0.501
<i>Dialister</i>	26.11	58.22	0.03	0.943
<i>Roseburia</i>	28.56	6.00	0.95	0.674
<i>Blautia</i>	32.44	49.44	5.08	0.156
<i>Coprococcus</i>	45.78	66.44	1.64	0.501
<i>Ruminococcus</i>	54.22	39.33	3.29	0.261
<i>Faecalibacterium</i>	154.89	93.11	7.75	0.080
Proteobacteria				
<i>Escherichia</i>	0.78	1.44	0.00	0.960
<i>Sutterella</i>	4.00	32.44	0.22	0.894
<i>Haemophilus</i>	10.67	0.56	6.72	0.107
<i>Bilophila</i>	10.67	7.67	0.10	0.896
Verrucomicrobia				
<i>Akkermansia</i>	17.00	3.33	1.67	0.501

<sup>1</sup>Replicate samples were pooled among donor at each respective time point (3 donors x 3 replicated = 9). Samples were analyzed between differentially represented OTUs for significant changes after 24 h of fermentation compared to 0 h samples. Data were analyzed using the Kruskal-Wallis ANOVA test, with the FDR multiple comparisons correction. \* Indicates significance at  $P \leq 0.05$ .

**Table 5.** Combined changes across 24 h of fermentation for xylooligosaccharide samples of identified phyla and genera.<sup>1</sup>

Phyla & Genera	0 h	24 h	Test-Statistic	P-value
Actinobacteria				
<i>Bifidobacterium</i>	0.67	5.22	9.11	0.038*
<i>Adlercreutzia</i>	1.33	1.78	0.08	0.972
<i>Collinsella</i>	58.44	154.00	1.87	0.413
Bacteroidetes				
<i>Alistipes</i>	1.44	0.56	1.85	0.413
<i>Parabacteroides</i>	147.33	133.33	0.02	0.972
<i>Bacteroides</i>	770.89	870.44	4.31	0.189
Firmicutes				
<i>Eubacterium</i>	0.33	1.67	2.75	0.364
<i>Veillonella</i>	0.67	0.00	4.78	0.162
<i>Acidaminococcus</i>	1.33	2.33	0.03	0.972
<i>Dorea</i>	2.11	3.67	1.70	0.423
<i>SMB53</i>	7.33	5.44	1.14	0.558
<i>Anaerostipes</i>	7.44	3.44	1.51	0.447
<i>Turicibacter</i>	8.00	8.56	0.02	0.972
<i>Clostridium</i>	8.44	4.00	6.51	0.087
<i>Ruminococcus</i>	12.78	26.11	6.58	0.087
<i>Streptococcus</i>	14.11	4.67	2.46	0.367
<i>Lachnospira</i>	21.11	5.33	9.37	0.038*
<i>Oscillospira</i>	21.33	21.78	0.02	0.972
<i>Phascolarctobacterium</i>	23.44	16.33	0.10	0.972
<i>Lactococcus</i>	23.89	21.00	0.00	0.982
<i>Roseburia</i>	28.89	35.33	0.16	0.972
<i>Dialister</i>	33.89	41.56	0.42	0.831
<i>Blautia</i>	39.22	65.00	6.37	0.087
<i>Ruminococcus</i>	45.11	37.33	2.13	0.385
<i>Coprococcus</i>	47.11	48.67	0.78	0.705
<i>Faecalibacterium</i>	148.56	79.56	11.56	0.030*
Proteobacteria				
<i>Escherichia</i>	0.89	0.44	0.07	0.972
<i>Haemophilus</i>	6.44	3.11	0.03	0.972
<i>Bilophila</i>	17.78	6.22	5.73	0.107
<i>Sutterella</i>	25.78	40.89	0.43	0.831
Verrucomicrobia				
<i>Akkermansia</i>	2.78	5.00	0.34	0.841

<sup>1</sup>Replicate samples were pooled among donor at each respective time point (3 donors x 3 replicated = 9). Samples were analyzed between differentially represented OTUs for significant changes after 24 h of fermentation compared to 0 h samples. Data were analyzed using the Kruskal-Wallis ANOVA test, with the FDR multiple comparisons correction. \* Indicates significance at P≤ 0.05.

**Table 6.** Combined changes across 24 h of fermentation for pure inulin samples of identified phyla and genera.<sup>1</sup>

Phyla & Genera	0 h	24 h	Test-Statistic	P-value
Actinobacteria				
<i>Bifidobacterium</i>	1.33	5.44	3.94	0.304
<i>Adlercreutzia</i>	1.33	2.00	0.47	0.845
<i>Collinsella</i>	55.11	291.44	12.79	0.016*
Bacteroidetes				
<i>Alistipes</i>	1.56	0.89	0.36	0.878
<i>Parabacteroides</i>	147.44	164.78	0.28	0.887
<i>Bacteroides</i>	726.78	644.44	1.64	0.652
Firmicutes				
<i>Veillonella</i>	0.78	0.56	0.03	0.908
<i>Eubacterium</i>	0.89	1.56	0.02	0.908
<i>Dorea</i>	1.78	7.00	1.96	0.640
<i>Acidaminococcus</i>	3.11	18.67	0.22	0.887
<i>SMB53</i>	7.44	9.11	0.00	0.965
<i>Turicibacter</i>	7.78	4.89	1.06	0.652
<i>Clostridium</i>	8.22	7.11	0.51	0.845
<i>Ruminococcus</i>	9.56	34.11	3.61	0.309
<i>Anaerostipes</i>	11.22	4.67	1.17	0.652
<i>Streptococcus</i>	13.00	12.44	0.16	0.887
<i>Lactococcus</i>	19.11	9.67	0.02	0.908
<i>Lachnospira</i>	21.00	4.89	10.85	0.022*
<i>Phascolarctobacterium</i>	26.22	21.00	0.16	0.887
<i>Oscillospira</i>	26.33	10.11	9.30	0.034*
<i>Roseburia</i>	26.78	14.11	0.28	0.887
<i>Dialister</i>	32.67	95.11	0.16	0.887
<i>Blautia</i>	38.22	50.22	0.86	0.690
<i>Coproccoccus</i>	48.11	60.89	1.88	0.640
<i>Ruminococcus</i>	52.33	43.00	0.10	0.908
<i>Faecalibacterium</i>	148.11	187.33	1.22	0.652
Proteobacteria				
<i>Escherichia</i>	1.00	1.22	0.04	0.908
<i>Haemophilus</i>	9.11	2.67	1.45	0.652
<i>Sutterella</i>	14.00	31.22	0.02	0.908
<i>Bilophila</i>	16.89	7.78	3.31	0.309
<i>Akkermansia</i>	7.78	7.44	4.02	0.304

<sup>1</sup>Replicate samples were pooled among donor at each respective time point (3 donors x 3 replicated = 9). Samples were analyzed between differentially represented OTUs for significant changes after 24 h of fermentation compared to 0 h samples. Data were analyzed using the Kruskal-Wallis ANOVA test, with the FDR multiple comparisons correction. \* Indicates significance at P ≤ 0.05.

**Table 7.** Combined changes across 24 h of fermentation for pure beta-glucan samples of identified phyla and genera.<sup>1</sup>

Phyla & Genera	0 h	24 h	Test-Statistic	P-value
Actinobacteria				
<i>Bifidobacterium</i>	0.33	0.33	0.00	1.000
<i>Adlercreutzia</i>	2.00	1.89	0.07	0.843
<i>Collinsella</i>	69.22	85.11	0.86	0.723
Bacteroidetes				
<i>Alistipes</i>	0.78	0.89	0.32	0.778
<i>Parabacteroides</i>	119.56	179.78	0.56	0.778
<i>Bacteroides</i>	776.11	854.33	1.03	0.664
Firmicutes				
<i>Eubacterium</i>	0.11	0.44	0.46	0.778
<i>Veillonella</i>	0.56	0.22	0.38	0.778
<i>Dorea</i>	0.89	3.11	7.06	0.110
<i>Acidaminococcus</i>	2.33	15.11	0.22	0.778
<i>SMB53</i>	6.11	4.89	0.39	0.778
<i>Lactococcus</i>	6.11	0.67	0.22	0.778
<i>Anaerostipes</i>	7.44	5.22	0.40	0.778
<i>Turicibacter</i>	8.11	3.00	0.13	0.803
<i>Ruminococcus</i>	9.44	18.67	4.35	0.166
<i>Clostridium</i>	10.11	3.33	6.38	0.110
<i>Streptococcus</i>	14.89	6.44	3.32	0.256
<i>Roseburia</i>	16.11	54.33	1.54	0.510
<i>Lachnospira</i>	21.22	3.89	12.88	0.008*
<i>Oscillospira</i>	24.33	35.11	2.40	0.389
<i>Phascolarctobacterium</i>	29.00	125.33	3.03	0.283
<i>Dialister</i>	30.56	43.67	0.10	0.819
<i>Coproccoccus</i>	44.11	20.78	3.79	0.211
<i>Blautia</i>	45.11	68.11	2.13	0.408
<i>Ruminococcus</i>	59.67	44.44	1.64	0.500
<i>Faecalibacterium</i>	152.11	62.67	12.82	0.008*
Proteobacteria				
<i>Escherichia</i>	0.89	0.56	0.31	0.778
<i>Haemophilus</i>	11.00	0.78	5.45	0.110
<i>Sutterella</i>	14.00	35.44	0.22	0.778
<i>Bilophila</i>	14.44	13.89	0.20	0.778
Verrucomicrobia				
<i>Akkermansia</i>	9.11	15.89	0.45	0.778

<sup>1</sup>Replicate samples were pooled among donor at each respective time point (3 donors x 3 replicated = 9). Samples were analyzed between differentially represented OTUs for significant changes after 24 h of fermentation compared to 0 h samples. Data were analyzed using the Kruskal-Wallis ANOVA test, with the FDR multiple comparisons correction. \* Indicates significance at P≤ 0.05.

**4. Discussion**

The aim of this study was to investigate the beneficial effects of commonly consumed prebiotic dietary fibers, including their ability to influence the growth of identified bacterial populations, form beneficial SCFAs, and the amount of gas they produce due to fermentation. Total gas production due to fiber fermentation depends on a wide range of factors. The inulin samples and the WholeFiber samples (mixture of dried chicory root inulin, pectin and hemi/cellulose) resulted in the

highest gas production at both 12 and 24 h. These results are consistent with results from both clinical feeding studies and other in vitro experiments, in which fermentation of inulin products resulted in high amounts of gas production, sometimes resulting in mild negative GI symptoms, depending on the dosage [29,30]. Similar in vitro studies have found inulin to be much more fermentable than beta-glucan products, for both barley and oat-derived beta-glucans [31]. XOS fermentation results in less gas production than the inulin products, and more gas than beta-glucan products. Because of these findings, previous studies based on digestive tolerance and parameters have established a tolerated daily dosage of approximately 12 g/d [32].

SCFA production due to the fermentation of prebiotic dietary fibers promotes many beneficial health outcomes to the host. SCFA production may contribute to up to 10% of the host's metabolizable energy daily, with production of total SCFAs usually between 100-200 mM/d, but is highly dependent on the donor and availability of substrates for fermentation [33,34]. At 12 h of fermentation, the OatWell and beta-glucan samples had significantly higher concentrations of propionate, and the highest mean concentration at 24 h compared to the other prebiotic dietary fibers analyzed. Similar in vitro studies with beta-glucan based products have also shown similar preference for these products to result in propionate formation [31]. Although no mechanism has been identified, and studies show conflicting results results [35], elevated serum propionate concentrations have been shown to have a hypocholesterolaemic effect [36]. Propionate may also play an influential role in satiety, although mechanisms still remain unclear [37,38]. Cholesterol-lowering properties of beta-glucans may be limited to effects from the upper-GI, although many propionate-producing bacteria have a preference to fermenting various types of beta-glucans (*Bacteroides*, *Prevotella*, *Clostridium*) based on the presence of genes responsible for endo- $\beta$ -glucanase enzyme production [39].

Microbial diversity among fecal donors complicates the identification of trends among the five treatment groups (Supplemental Figures 8 and 9). In terms of taxonomic shift, the inulin-based products were fermented nearly identically by all three fecal donors. Both pure inulin and WholeFiber promoted the growth of *Collinsella* comparing the 24 h samples to 0 h samples. Inulin-type fructans have been shown in clinical studies to promote substantial growth of *Collinsella*, paralleled with increased urinary hippurate levels [40]. Hippurate is a metabolite derived from various fermentation processes in the gut that has been found in decreased concentrations in obese individuals compared to lean individuals, and also between diabetics and non-diabetics [41–43]. The genus *Collinsella* has been found in lower concentrations in individuals with IBD compared to healthy controls[44], while *Collinsella aerofaciens* has been associated with low risk of colorectal cancer [45]. Increases in *Collinsella* and increased urinary hippurate levels are considered a beneficial effect of inulin consumption due to its prebiotic capacity [40].

A significant increase in the genus *Bifidobacterium* was observed only with the XOS treatment. Increases in *Bifidobacterium* have been heavily studied and reviewed, and are considered a beneficial effect due to their correlation with many positive health outcomes [1]. *Bifidobacteria* reside naturally in the gastrointestinal tract of healthy human adults and have a strong affinity to ferment oligosaccharides, making them a common marker for prebiotic capacity. *Bifidobacterium* is a unique

genus of bacteria in that no gas is formed as an end product of metabolism [46]. Like *Lactobacillus*, these bacteria are saccharolytic, often considered a beneficial trait [47]. *Bifidobacteria* also do not produce any known carcinogenic substances in vivo. *Bifidobacteria* concentrations have been negatively associated with obesity and weight gain.[48–51] Increases in *Bifidobacteria* have also been correlated with a decrease in blood lipopolysaccharides (LPS), inflammatory reagents that play a role in the development of inflammatory metabolic disorders and conditions, and are primarily found in gram-negative bacteria [52]. LPS induce the activation of Toll-like receptor 4 (TLR4), which leads to inflammation due to release of pro-inflammatory cytokines and chemokines [53].

In vitro fermentations are semi-representative models of colonic fermentation, but have limitations [18]. This study did not include an in vitro digestion process, which would remove digestible contents from the samples prior to fermentation, and would be a more representative model. However, because the test substrates are primarily fiber, which is non-digestible, this should have minimal impact on the results of this study. In vivo, formed gases are continually absorbed and colonic absorption is rapid. Because SCFAs are rapidly absorbed and difficult to measure, in vitro models help to understand the kinetics of colonic fermentation. However, in vitro models must be paired with similar in vivo models to better understand the full mechanisms of action resulting from colonic fermentation of prebiotic dietary fibers.

**5. Conclusions**

All five prebiotics measured in this study offer specific health benefits that can be attributed to their fermentation. Depending on their structure, each compound offers a specific carbon source for fermentation by different bacterial populations, yielding changes in beneficial taxa and production of various amounts of SCFAs and gas in vitro. For instance, while OatWell and beta-glucans promoted propionate production, XOS increased concentrations of *Bifodobacterium*, and WholeFiber and pure inulin promoted *Collinsella* growth. Findings in this study are consistent to other in vitro studies with similar prebiotic dietary fibers, as well as numerous clinical feeding studies.



358 **Supplementary Materials:** Supplementary Materials are available online.

359 **Acknowledgments:** The authors would like to thank Hannah Paruzynski for the laboratory assistance, the  
360 University of Minnesota Genomics Center for the analysis of the samples, The University of Minnesota Doctoral  
361 Dissertation Fellowship for financial research support, and the companies who donated time and resources to  
362 this project.

363 **Author Contributions:** JS and JC conceived and designed the experiment; JC, JE and JH performed the  
364 experiments. JC analyzed the data, TG was responsible for analysis of sequencing data. Manuscript was  
365 prepared by JC and JE, and read and approved by all authors.

366 **Conflicts of Interest:** The authors declare no conflict of interest. The founding sponsors had no role in the  
367 design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in  
368 the decision to publish the results.

369

370 **References**

- 371 1. Carlson, J.; Slavin, J. Health benefits of fibre, prebiotics and probiotics: a review of intestinal health and  
372 related health claims. *Qual. Assur. Saf. Crop. Foods* **2016**, *6*, 1–16, doi:10.3920/QAS2015.0791.
- 373 2. Brownawell, A. M.; Caers, W.; Gibson, G. R.; Kendall, C. W. C.; Lewis, K. D.; Ringel, Y.; Slavin, J. L.  
374 Prebiotics and the Health Benefits of Fiber: Current Regulatory Status, Future Research, and Goals. *J.*  
375 *Nutr.* **2012**, *142*, 962–974, doi:10.3945/jn.112.158147.
- 376 3. Gibson, G. R.; Scott, K. P.; Rastall, R. A.; Tuohy, K. M.; Hotchkiss, A.; Dubert-Ferrandon, A.; Gareau, M.;  
377 Murphy, E. F.; Saulnier, D.; Loh, G.; Macfarlane, S.; Delzenne, N.; Ringel, Y.; Kozianowski, G.;  
378 Dickmann, R.; Lenoir-Wijnkoop, I.; Walker, C.; Buddington, R. Dietary prebiotics: current status and  
379 new definition. *Food Sci. Technol. Bull. Funct. Foods* **2010**, *7*, 1–19, doi:10.1616/1476-2137.15880.
- 380 4. Gibson, G. R.; Roberfroid, M. B. Dietary modulation of the human colonic microbiota: introducing the  
381 concept of prebiotics. *J. Nutr.* **1995**, *125*, 1401–1412, doi:10.1079/NRR200479.
- 382 5. Gibson, G. R.; Probert, H. M.; Loo, J. Van; Rastall, R. A.; Roberfroid, M. B. Dietary modulation of the  
383 human colonic microbiota: updating the concept of prebiotics. *Nutr. Res. Rev.* **2004**, *17*, 259–75,  
384 doi:10.1079/NRR200479.
- 385 6. Slavin, J. Fiber and prebiotics: mechanisms and health benefits. *Nutrients* **2013**, *5*, 1417–35,  
386 doi:10.3390/nu5041417.
- 387 7. Bindels, L. B.; Delzenne, N. M.; Cani, P. D.; Walter, J. Towards a more comprehensive concept for  
388 prebiotics. *Nat. Publ. Gr.* **2015**, doi:10.1038/nrgastro.2015.47.
- 389 8. Aachary, A. A.; Prapulla, S. G. Xylooligosaccharides (XOS) as an Emerging Prebiotic: Microbial  
390 Synthesis, Utilization, Structural Characterization, Bioactive Properties, and Applications. *Compr. Rev.*  
391 *Food Sci. Food Saf.* **2011**, *10*, 2–16, doi:10.1111/j.1541-4337.2010.00135.x.
- 392 9. Vázquez, M. ;; Alonso, J. ;; Domínguez, H.; Parajó, J. . Xylooligosaccharides: manufacture and  
393 applications. *Trends Food Sci. Technol.* **2000**, *11*, 387–393, doi:10.1016/S0924-2244(01)00031-0.
- 394 10. Christakopoulos, P.; Katapodis, P. Antimicrobial activity of acidic xylo-oligosaccharides produced by  
395 family 10 and 11 endoxylanases. *Int. J. Biol. Macromol.* **2003**, *31*, 171–175.
- 396 11. Katapodis, P.; Kavarnou, A.; Kintzios, S. Production of acidic xylo-oligosaccharides by a family 10  
397 endoxylanase from *Thermoascus aurantiacus* and use as plant growth regulators. *Biotechnol. Lett.* **2002**,  
398 *24*, 1413–1416.
- 399 12. Vardakou, M.; Katapodis, P.; Topakas, E.; Kekos, D.; Macris, B. J.; Christakopoulos, P. Synergy between  
400 enzymes involved in the degradation of insoluble wheat flour arabinoxylan. *Innov. Food Sci. Emerg.*  
401 *Technol.* **2004**, *5*, 107–112, doi:10.1016/S1466-8564(03)00044-4.
- 402 13. Yang, R.; Xu, S.; Wang, Z.; Yang, W. Aqueous extraction of corn cob xylan and production of  
403 xylooligosaccharides. *LWT-Food Sci. Technol.* **2005**, *38*, 677–682.
- 404 14. Yuan, Q.; Zhang, H. Pilot-plant production of xylo-oligosaccharides from corn cob by steaming,  
405 enzymatic hydrolysis and nanofiltration. *J. Chem. Technol. Biotechnol.* **2004**, *78*, 1073–1079.
- 406 15. Niness, K. R. Inulin and Oligofructose: What Are They? *J. Nutr.* **1999**, *129*, 1402-.
- 407 16. Carpita, N. C.; Kanabus, J.; Housley, T. L. Linkage Structure of Fructans and Fructan Oligomers from  
408 *Triticum aestivum* and *Festuca arundinacea* Leaves. *J. Plant Physiol.* **1989**, *134*, 162–168,  
409 doi:10.1016/S0176-1617(89)80050-1.
- 410 17. Lam, K. L.; Chi-Keung Cheung, P. Non-digestible long chain beta-glucans as novel prebiotics. *Bioact.*  
411 *Carbohydrates Diet. Fibre* **2013**, *2*, 45–64, doi:10.1016/j.bcdf.2013.09.001.
- 412 18. Wisker, E.; Daniel, M. Fermentation of non-starch polysaccharides in mixed diets and single fibre

- sources: comparative studies in human subjects and in vitro. *Br. J.* **1998**.
19. Payne, A. N.; Zihler, A.; Chassard, C.; Lacroix, C. Advances and perspectives in in vitro human gut fermentation modeling. *Trends Biotechnol.* **2012**, *30*, 17–25, doi:10.1016/j.tibtech.2011.06.011.
  20. Gibson, G. R.; Hutkins, R.; Sanders, M. E.; Prescott, S. L.; Reimer, R. A.; Salminen, S. J.; Scott, K.; Stanton, C.; Swanson, K. S.; Cani, P. D.; Verbeke, K.; Reid, G. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat. Rev. Gastroenterol. Hepatol.* **2017**, doi:10.1038/nrgastro.2017.75.
  21. Schneider, S. M.; Girard-Pipau, F.; Anty, R.; van der Linde, E. G. M.; Philipsen-Geerling, B. J.; Knol, J.; Filippi, J.; Arab, K.; Hébuterne, X. Effects of total enteral nutrition supplemented with a multi-fibre mix on faecal short-chain fatty acids and microbiota. *Clin. Nutr.* **2006**, *25*, 82–90, doi:10.1016/j.clnu.2005.09.006.
  22. Carlson, J.; Hospattankar, A.; Deng, P.; Swanson, K.; Slavin, J. Prebiotic Effects and Fermentation Kinetics of Wheat Dextrin and Partially Hydrolyzed Guar Gum in an In Vitro Batch Fermentation System. *Foods* **2015**, *4*, 349–358, doi:10.3390/foods4030349.
  23. Caporaso, J. G.; Kuczynski, J.; Stombaugh, J.; Bittinger, K.; Bushman, F. D.; Costello, E. K.; Fierer, N.; Peña, A. G.; Goodrich, J. K.; Gordon, J. I.; Huttley, G. A.; Kelley, S. T.; Knights, D.; Koenig, J. E.; Ley, R. E.; Lozupone, C. A.; McDonald, D.; Muegge, B. D.; Pirrung, M.; Reeder, J.; Sevinsky, J. R.; Turnbaugh, P. J.; Walters, W. A.; Widmann, J.; Yatsunenko, T.; Zaneveld, J.; Knight, R. QIIME allows analysis of high-throughput community sequencing data. *Nat. Methods* **2010**, *7*, 335–6, doi:10.1038/nmeth.f.303.
  24. Garbe, J.; Gould, T.; Gohl, D.; Knights, D.; Beckman, K. Gopher-Pipelines Version 1 2016.
  25. Bolger, A. M.; Lohse, M.; Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* **2014**, *30*, 2114–20, doi:10.1093/bioinformatics/btu170.
  26. Masella, A. P.; Bartram, A. K.; Truszkowski, J. M.; Brown, D. G.; Neufeld, J. D. PANDASEQ: paired-end assembler for illumina sequences. *BMC Bioinformatics* **2012**, *13*, 31, doi:10.1186/1471-2105-13-31.
  27. Liu, T.-W.; Cephas, K. D.; Holscher, H. D.; Kerr, K. R.; Mangian, H. F.; Tappenden, K. A.; Swanson, K. S. Nondigestible fructans alter gastrointestinal barrier function, gene expression, histomorphology, and the microbiota profiles of diet-induced obese C57BL/6J Mice. *J. Nutr.* **2016**, *146*, 949–956, doi:10.3945/jn.115.227504.
  28. Goldsmith, F.; Guice, J.; Page, R.; Welsh, D. A.; Taylor, C. M.; Blanchard, E. E.; Luo, M.; Raggio, A. M.; Stout, R. W.; Carvajal-Aldaz, D.; Gaither, A.; Pelkman, C.; Ye, J.; Martin, R. J.; Geaghan, J.; Durham, H. A.; Coulon, D.; Keenan, M. J. Obese ZDF rats fermented resistant starch with effects on gut microbiota but no reduction in abdominal fat. *Mol. Nutr. Food Res.* **2016**, *61*, 1–10, doi:10.1002/mnfr.201501025.
  29. Bonnema, A. L.; Kolberg, L. W.; Thomas, W.; Slavin, J. L. Gastrointestinal tolerance of chicory inulin products. *J. Am. Diet. Assoc.* **2010**, *110*, 865–8, doi:10.1016/j.jada.2010.03.025.
  30. Timm, D. A.; Stewart, M. L.; Hospattankar, A.; Slavin, J. L. Wheat Dextrin, Psyllium, and Inulin Produce Distinct Fermentation Patterns, Gas Volumes, and Short-Chain Fatty Acid Profiles In Vitro. *J. Med. Food* **2010**, *13*, 961–966, doi:10.1089/jmf.2009.0135.
  31. Hughes, S. A.; Shewry, P. R.; Gibson, G. R.; McCleary, B. V.; Rastall, R. A. In vitro fermentation of oat and barley derived  $\beta$ -glucans by human faecal microbiota. *FEMS Microbiol. Ecol.* **2008**, *64*, 482–493, doi:10.1111/j.1574-6941.2008.00478.x.
  32. Xiao, L.; Ning, J.; Xu, G. Application of Xylo-oligosaccharide in modifying human intestinal function. *African J. Microbiol. Res.* **2012**, *6*, 2116–2119, doi:10.5897/.
  33. Livesey, G. Energy values of unavailable carbohydrate and diets: an inquiry and analysis. *Am J Clin*

- Nutr* **1990**, *51*, 617–637.
34. Cook, S. I.; Sellin, J. H. Review article: short chain fatty acids in health and disease. *Aliment. Pharmacol. Ther.* **1998**, *12*, 499–507, doi:10.1046/j.1365-2036.1998.00337.x.
  35. Malkki, Y.; Autio, K.; Hanninen, O.; Myllymaki, O.; Pelkonen, K.; Suortti, T.; Torronen, R. *Oat bran concentrates: physical properties of beta-glucan and hypocholesterolemic effects in rats*; 1992;
  36. Chen, W.-J. L.; Anderson, J. W.; Jennings, D. Propionate May Mediate the Hypocholesterolemic Effects of Certain Soluble Plant Fibers in Cholesterol-Fed Rats. *Exp. Biol. Med.* **1984**, *175*, 215–218, doi:10.3181/00379727-175-41791.
  37. Chambers, E. S.; Morrison, D. J.; Frost, G.; Mozaffarian, D. Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms? *Proc. Nutr. Soc.* **2015**, *74*, 328–336, doi:10.1017/S0029665114001657.
  38. Chambers, E.; Viardot, A.; Psichas, A.; Morrison, D. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. *Gut* **2015**, *64*, 1744–1754.
  39. Zappe, H.; Jones, W. A.; Jones, D. T.; Woods, D. R. Structure of an endo-beta-1,4-glucanase gene from *Clostridium acetobutylicum* P262 showing homology with endoglucanase genes from *Bacillus* spp. *Appl. Environ. Microbiol.* **1988**, *54*, 1289–92.
  40. Dewulf, E. M.; Cani, P. D.; Claus, S. P.; Fuentes, S.; Puylaert, P. G.; Neyrinck, A. M.; Bindels, L. B.; de Vos, W. M.; Gibson, G. R.; Thissen, J.-P.; Delzenne, N. M. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. *Gut* **2013**, *62*, 1112–1121, doi:10.1136/gutjnl-2012-303304.
  41. Calvani, R.; Miccheli, A.; Capuani, G.; Tomassini Miccheli, A.; Puccetti, C.; Delfini, M.; Iaconelli, A.; Nanni, G.; Mingrone, G. Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype. *Int. J. Obes.* **2010**, *34*, 1095–1098, doi:10.1038/ijo.2010.44.
  42. Salek, R. M.; Maguire, M. L.; Bentley, E.; Rubtsov, D. V.; Hough, T.; Cheeseman, M.; Nunez, D.; Sweatman, B. C.; Haselden, J. N.; Cox, R. D.; Connor, S. C.; Griffin, J. L. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. *Physiol. Genomics* **2007**, *29*, 99–108, doi:10.1152/physiolgenomics.00194.2006.
  43. Waldram, A.; Holmes, E.; Wang, Y.; Rantalainen, M.; Wilson, I. D.; Tuohy, K. M.; McCartney, A. L.; Gibson, G. R.; Nicholson, J. K. Top-Down Systems Biology Modeling of Host Metabotype–Microbiome Associations in Obese Rodents. *J. Proteome Res.* **2009**, *8*, 2361–2375, doi:10.1021/pr8009885.
  44. Kassinen, A.; Krogius-Kurikka, L.; Mäkituokko, H.; Rinttilä, T.; Paulin, L.; Corander, J.; Malinen, E.; Apajalahti, J.; Palva, A. The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly From That of Healthy Subjects. *Gastroenterology* **2007**, *133*, 24–33, doi:10.1053/j.gastro.2007.04.005.
  45. Moore, W. E.; Moore, L. H. Intestinal floras of populations that have a high risk of colon cancer. *Appl. Environ. Microbiol.* **1995**, *61*, 3202–7.
  46. Buchanan, R.; Gibbons, N. *Bergey's Manual of Determinative Bacteriology*; 1974;
  47. SALYERS, A. Energy sources of major intestinal fermentative anaerobes. *Am. J. Clin. Nutr.* **1979**, *32*, 158–163.
  48. Collado, M.; Isolauri, E. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. *Am. J. Clin. Nutr.* **2008**, *55*, 894–899.
  49. Kalliomäki, M.; Collado, M. Early differences in fecal microbiota composition in children may predict overweight. *Am. J. Clin. Nutr.* **2008**, *87*, 534–538.

499 50. Santacruz, A. Gut microbiota composition is associated with body weight, weight gain and biochemical  
500 parameters in pregnant women. *Br. J. Nutr.* **2010**, *104*, 83–84.

501 51. Schwartz, A.; Taras, D.; Schäfer, K.; Beijer, S. Microbiota and SCFA in lean and overweight healthy  
502 subjects. *Obesity* **2010**, *18*, 190–195.

503 52. Knaapen, M.; Kootte, R. S.; Zoetendal, E. G.; de Vos, W. M.; Dallinga-Thie, G. M.; Levi, M.; Stoes, E. S.;  
504 Nieuwdorp, M. Obesity, non-alcoholic fatty liver disease, and atherothrombosis: a role for the intestinal  
505 microbiota? *Clin. Microbiol. Infect.* **2013**, *19*, 331–337, doi:10.1111/1469-0691.12170.

506 53. Nakamura, Y.; Omaye, S. Metabolic diseases and pro-and prebiotics: mechanistic insights. *Nutr. Metab.*  
507 *(Lond)*. **2012**, *9*, 1–11.

508